- Home
- JBTM vs BLCO Comparison
JBTM vs BLCO Comparison
Compare JBTM & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBTM
- BLCO
- Stock Information
- Founded
- JBTM 1994
- BLCO 1853
- Country
- JBTM United States
- BLCO Canada
- Employees
- JBTM N/A
- BLCO N/A
- Industry
- JBTM
- BLCO Ophthalmic Goods
- Sector
- JBTM
- BLCO Health Care
- Exchange
- JBTM Nasdaq
- BLCO Nasdaq
- Market Cap
- JBTM 6.4B
- BLCO 6.3B
- IPO Year
- JBTM N/A
- BLCO 2022
- Fundamental
- Price
- JBTM $118.92
- BLCO $15.77
- Analyst Decision
- JBTM Strong Buy
- BLCO Buy
- Analyst Count
- JBTM 1
- BLCO 12
- Target Price
- JBTM $143.00
- BLCO $19.82
- AVG Volume (30 Days)
- JBTM 375.5K
- BLCO 751.8K
- Earning Date
- JBTM 02-24-2025
- BLCO 02-19-2025
- Dividend Yield
- JBTM 0.08%
- BLCO N/A
- EPS Growth
- JBTM N/A
- BLCO N/A
- EPS
- JBTM 5.38
- BLCO N/A
- Revenue
- JBTM $1,693,000,000.00
- BLCO $4,791,000,000.00
- Revenue This Year
- JBTM $6.46
- BLCO $17.29
- Revenue Next Year
- JBTM $4.29
- BLCO $5.47
- P/E Ratio
- JBTM $26.61
- BLCO N/A
- Revenue Growth
- JBTM 1.93
- BLCO 15.56
- 52 Week Low
- JBTM $82.64
- BLCO $13.16
- 52 Week High
- JBTM $133.98
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- JBTM N/A
- BLCO 32.89
- Support Level
- JBTM N/A
- BLCO $15.62
- Resistance Level
- JBTM N/A
- BLCO $16.60
- Average True Range (ATR)
- JBTM 0.00
- BLCO 0.46
- MACD
- JBTM 0.00
- BLCO -0.05
- Stochastic Oscillator
- JBTM 0.00
- BLCO 7.01
About JBTM JBT Marel Corporation
JBT Marel Corp is a technology solutions provider to segments of the food and beverage industry. It designs, produces, and services products and systems for a broad range of end markets, generating roughly one-half of annual revenue from recurring parts, services, rebuilds, and leasing operations.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.